CTNNB1 and neoplasm: CTNNB1 status can be used to stratify FIGO stage I tumours into group with a favourable prognosis (CTNNB1-wild type, with a similar prognosis to POLEmut tumors) and group with an unfavourable prognosis (CTNNB1-mutant, with a similar prognosis to MMRd) [51].